Endobronchial Ultrasound Biopsy Market (2026 - 2036)

Endobronchial Ultrasound Biopsy Market Forecast and Outlook 2026 to 2036

In 2025, the endobronchial ultrasound biopsy market was valued at approximately USD 0.75 billion, modestly adjusted from baseline estimates. Based on Fact.MR analysis, demand for endobronchial ultrasound biopsy systems and consumables is estimated to reach around USD 0.80 billion in 2026 and expand to nearly USD 1.48 billion by 2036, reflecting a CAGR of 6.3% during the forecast period. Market progression reflects increased lung cancer screening programs and growing reliance on minimally invasive mediastinal staging. Commenting on imaging integration trends, Dave Rosa, CEO of Intuitive Surgical, stated,“By further integrating artificial intelligence with expanded advanced imaging capabilities, we're equipping physicians with smarter tools designed to support early diagnosis and improve access to advanced care for more patients.” [1]Fact.MR analysis interprets this as indicative of broader diagnostic platform convergence combining imaging, navigation, and AI-assisted visualization.

The market is projected to add roughly USD 0.73 billion in incremental value over the forecast window, reflecting steady procedural growth rather than episodic spikes. Early-period expansion is supported by increased CP-EBUS adoption in academic hospitals. Mid-period growth aligns with wider deployment in community hospitals and specialty pulmonary clinics. In later years, value realization is shaped by advanced imaging processors, disposable biopsy needle innovation, and integration with robotic bronchoscopy systems.

China leads growth at 8.5% CAGR, supported by expanding tertiary care infrastructure and oncology diagnostics. India follows at 7.9%, driven by rising lung cancer incidence and private hospital expansion. Germany records 7.2%, reflecting structured cancer screening programs. France grows at 6.6%, while the United Kingdom posts 6.0% linked to NHS diagnostic pathway optimization. The United States, at 5.4%, remains influenced by reimbursement structures and established procedural penetration, while Brazil at 4.7% reflects gradual adoption across urban healthcare centers.

Endobronchial Ultrasound Biopsy MarketTop of Form

Summary of Endobronchial Ultrasound Biopsy Market

• Market Definition
  • The endobronchial ultrasound biopsy market comprises minimally invasive bronchoscopy-based ultrasound systems and biopsy consumables used for real-time guided sampling of mediastinal lymph nodes and pulmonary lesions for lung cancer diagnosis and staging.
• Demand Drivers
  • Expansion of lung cancer screening programs is increasing procedural volumes for minimally invasive mediastinal staging.
  • Clinical preference for image-guided, less invasive biopsy techniques is reducing reliance on surgical mediastinoscopy.
  • Integration of advanced imaging processors and disposable EBUS-TBNA needles is improving diagnostic yield and workflow efficiency in tertiary hospitals.
• Key Segments Analyzed
  • Product outlook: EBUS scopes hold approximately 36% share, reflecting their role as core capital equipment integrating bronchoscopy and ultrasound imaging.
  • Procedure outlook: Convex-probe linear EBUS systems account for nearly 45% share due to direct transbronchial needle aspiration capability.
  • Geography: Asia Pacific is the fastest-growing region, led by China and India through oncology infrastructure expansion.
• Analyst Opinion at Fact.MR
  • Shambhu Nath Jha, Principal Consultant at Fact.MR, opines, ‘CXOs will find this report useful for understanding how lung cancer staging protocols, reimbursement dynamics, and integration with advanced imaging platforms are shaping capital equipment and consumable demand in EBUS biopsy procedures.’
• Strategic Implications / Executive Takeaways
  • Manufacturers should prioritize high-resolution imaging integration and needle accuracy improvements to enhance diagnostic yield.
  • Expansion strategies should focus on tertiary care hospitals and academic centers adopting standardized lung cancer pathways.
  • Partnerships aligned with robotic bronchoscopy and AI-assisted imaging platforms can strengthen long-term portfolio positioning.
• Methodology
  • Market estimates are derived from lung cancer incidence data, biopsy procedure volumes, device utilization rates, and hospital replacement cycles.
  • Regulatory and clinical validation references.

Endobronchial Ultrasound Biopsy Market Definition

The endobronchial ultrasound biopsy market covers minimally invasive diagnostic procedures and related medical devices used to obtain tissue samples from lymph nodes and lung structures through the airway. The technique combines bronchoscopy with ultrasound imaging to guide needle biopsy in real time. It is commonly used for lung cancer diagnosis, staging, and evaluation of mediastinal abnormalities. Device classification, safety standards, and clinical use are regulated under medical device frameworks administered by the US Food and Drug Administration and global health authorities. [2]

Endobronchial Ultrasound Biopsy Market Inclusions

The report provides global and regional market size estimates in volume and value with a forecast from 2026 to 2036. Segmentation includes device type such as ultrasound bronchoscopes and biopsy needles, application across lung cancer diagnosis and staging, and end use in hospitals and specialty diagnostic centers. Regional demand patterns, pricing trends, and procedural adoption rates are included.

Endobronchial Ultrasound Biopsy Market Exclusions

The scope excludes conventional bronchoscopy procedures without ultrasound guidance. CT guided needle biopsies, surgical lung biopsies, and imaging systems not integrated with bronchoscopy are not included. Cancer treatment modalities such as chemotherapy, radiotherapy, and surgical resection are excluded. Training services, laboratory research tools, prototype devices without regulatory clearance, and healthcare delivery services are also outside the scope.

Endobronchial Ultrasound Biopsy Market Research Methodology

• Primary Research: Interviews were conducted with pulmonologists, thoracic surgeons, hospital procurement teams, and device manufacturers.
• Desk Research: Desk research reviewed device approval databases, safety communications, and clinical guidance issued by the US Food and Drug Administration and public health information from the World Health Organization, along with hospital procedure statistics.
• Market Sizing and Forecasting: Estimates were developed using lung cancer incidence data, biopsy procedure volumes, device utilization rates, and replacement cycles.
• Data Validation and Update Cycle: Data was cross checked against regulatory approvals, hospital procurement records, trade statistics, and manufacturer disclosures before updates were finalized.

Endobronchial Ultrasound Biopsy Market Drivers, Restraints, And Opportunities

Fact.MR analysis indicates that the endobronchial ultrasound biopsy (EBUS biopsy) market exists as a specialised medical diagnostic and interventional segment focused on minimally invasive tissue sampling of mediastinal and pulmonary lesions. As per Fact.MR assessment, EBUS biopsy systems combine bronchoscope platforms with real-time ultrasound imaging and biopsy channel access, and their clinical use is shaped by medical device regulatory frameworks such as the U.S. Food and Drug Administration (FDA) medical device regulatory requirements, which define classification, performance evaluation, and post-market surveillance criteria for ultrasound-guided diagnostic tools and accessory biopsy instruments. Fact.MR analysts observe that the current market size is strongly influenced by rising incidence and early detection efforts in lung cancer, increasing clinical preference for minimally invasive diagnostics, and guideline recommendations that support EBUS biopsy as a standard staging and diagnostic modality in thoracic oncology.

Fact.MR is of the opinion that current market dynamics reflect a transition in clinical adoption toward integrated imaging, navigation, and sampling systems that improve diagnostic yield while reducing procedural invasiveness. Based on Fact.MR assessment, traditional bronchoscopy without ultrasound guidance remains in use for basic airway assessment due to cost and procedural familiarity, but demand for EBUS biopsy grows where higher diagnostic accuracy and real-time imaging are specified by pulmonary and oncology care pathways. Advanced EBUS biopsy solutions that offer enhanced image resolution, steerable biopsy instruments, and computer-assisted navigation generally carry higher per-unit pricing because of integrated technology and clinical validation requirements, meaning realised market value can grow even where procedural volume expansion is moderate. Fact.MR analysis suggests that this combination of evolving clinical expectations and premium system placement will shape near-term market progression.

• Regulatory medical device frameworks: Fact.MR analysts note that compliance with FDA medical device requirements influences design, testing, and market entry criteria for EBUS biopsy systems and related instruments intended for clinical diagnostic use.
• Shift to image-guided diagnostics: Based on Fact.MR assessment, increasing adoption of real-time ultrasound-guided sampling supports demand for EBUS biopsy technologies that improve lesion localisation, staging accuracy, and clinical decision support compared with conventional bronchoscopy.
• Asia Pacific clinical capacity growth: Fact.MR opines that expanding pulmonary care infrastructure, rising lung cancer incidence, and increased availability of advanced diagnostic services in China, India, and Southeast Asia support regional uptake of EBUS biopsy solutions across tertiary care facilities.

Competitive Landscape of Endobronchial Ultrasound Biopsy Market

As per Fact.MR analysis, the 2026 endobronchial ultrasound (EBUS) biopsy market is defined by validated imaging resolution, device reliability, and regulatory compliance, which determine competitive advantage. Olympus Corporation and GE HealthCare lead with high-precision EBUS systems and verified needle guidance performance, which strengthens adoption in pulmonary and thoracic oncology centers. Siemens Healthineers AG and Koninklijke Philips N.V. focus on integrated imaging platforms with validated real-time navigation and biopsy accuracy, which improves procedural outcomes and reduces complication rates. Boston Scientific Corporation and Cook Group provide validated endoscopic instruments with consistent performance and multi-region regulatory approvals, which supports hospital and clinic adoption. FUJIFILM Holdings Corporation and Medi-Globe Technologies GmbH emphasize high-resolution visualization and ergonomic device designs, which enhance clinician usability and procedural efficiency. ACE Medical Devices Pvt. Ltd. and Praxis Medical offer regionally compliant systems with documented reliability, which expands adoption in emerging markets. Across the market, validated imaging accuracy, procedural reliability, and regulatory adherence form enduring competitive moats, reducing reliance on pricing or isolated device claims.

Recent Industry Developments

• June 2024: American College of Chest Physicians (CHEST) announced a new guideline on collection, processing, and handling of EBUS-TBNA specimens, shaping clinical workflow expectations for biopsy programmes. [5]
• March 2024: NICE updated NG122 "Lung cancer: diagnosis and management", keeping UK staging and diagnostic pathway guidance current for service planning and procurement. [6]

Scope of the Report

Bibliography

• [1] Intuitive Surgical, Inc. (2024). Corporate statement on imaging integration and artificial intelligence in minimally invasive diagnostics [Executive commentary].
• [2] U.S. Food and Drug Administration. (2024). Medical device regulatory framework and device classification guidance. U.S. Department of Health and Human Services.
  World Health Organization. (2024). Cancer: Key facts and global health overview. World Health Organization.
• [3] U.S. Food and Drug Administration. (2024). Overview of medical devices and regulatory requirements. U.S. Department of Health and Human Services.
• [4] Centers for Disease Control and Prevention. (2024). Lung cancer: Prevention, screening, and statistics. U.S. Department of Health and Human Services.
• [5] American College of Chest Physicians (CHEST). (2024). Guideline on collection, processing, and handling of EBUS-TBNA specimens [Clinical practice guideline].
• [6] National Institute for Health and Care Excellence (NICE). (2024). NG122: Lung cancer-Diagnosis and management [Clinical guideline update].